Table 7.
Simulation results with data of A09712 with different values of β while α=−2 and wi=1 for all toxicities.
| Dose level | Probability (%) the dose chosen as maximum tolerated dose (MTD) | ||||
|---|---|---|---|---|---|
|
| |||||
| β=0.1 | β=0.25 | β=0.5 | β=1 | β=2 | |
| 1 | 0 | 0 | 0 | 0 | 0 |
| 2 | 0 | 0 | 0 | 0 | 0 |
| 3 | 0 | 0 | 0 | 0.05 | 0.3 |
| 4 | 0.01 | 0.02 | 0.02 | 0.07 | 0.2 |
| 5 | 0 | 0 | 0 | 0.02 | 0.2 |
| 6a | 1.6 | 2.0 | 2.9 | 7.0 | 20.2 |
| 7 | 7.3 | 8.0 | 11.1 | 23.0 | 34.5 |
| 8b | 83.5 | 83.7 | 83.0 | 69.9 | 44.6 |
| 9 | 7.5 | 6.3 | 3.1 | 0.03 | 0.01 |
| Average sample size | 41.0 (4.5) | 41.1 (4.7) | 41.1 (5.0) | 41.1 (5.9) | 40.0 (7.1) |
| Average number of cohorts | 13.7 (1.5) | 13.7 (1.6) | 13.7 (1.7) | 13.8 (2.0) | 13.3 (2.4) |
| Original sample size | 40 | ||||
| Original cohort number | 13 | ||||
a
The MTD recommended by original trial with Standard 3+3 design with dose de-escalation.
b
The most frequently recommended MTD by pseudo-trials with extended isotonic design (EID).